4th International Symposium on Pharmaceutical Sciences (ISOPS), Ankara, Türkiye, 25 - 28 Haziran 2024, ss.264
DEVELOPMENT AND CHARACTERIZATION OF
TAMOXIFEN CITRATE LOADED ɣ-CYCLODEXTRIN METAL ORGANIC FRAMEWORKS
1Mutlu Ağardan, NB,
1Edisan Ş.
1
Gazi University, Department of Pharmaceutical Technology, Ankara, Turkey,
bmutlu@gazi.edu.tr, seymaaydogduoglu@gazi.edu.tr
Introduction:ɣ-Cyclodextrin metal-organic frameworks (ɣ-CD-MOFs) are novel drug delivery systems prepared with
gamma-cyclodextrin and alkali metal cations which constitute a class of porous,
edible nanomaterials with high surface area (1). Tamoxifen citrate is widely
used for preventing recurrence of ER-positive breast cancers (2,3). It is a BCS
II drug, a weak base, characterized with rapid dissolution in the gastric
environment with possible precipitation expected due to the high pH in the duodenum
(4). In this study, it was aimed to increase the solubility of TMX by preparing
TMX-ɣ-CD-MOF formulations and fully characterize the TMX-ɣ-CD-MOFs.
Materials and Methods:Two
different ɣ-CD-MOF
were prepared by modified methanol diffusion method with slight modifications.
Tamoxifen was encapsulated in ɣ-CD-MOFs
via impregnation method at 60°C. Loading efficiency was measured by UV
spectrophotometry at 235 nm. Characterization studies were carried out using DLS,
SEM, DSC, XRD, BET techniques. Solubility
studies were performed with TMX-ɣ-CD-MOFs comparatively with pure drug and physical
mixture (1:1) in pH 1.2, pH 4.5 and pH 6.8 at 37°C and in water at 25°C.
Results:The
formulations were prepared by two methods were named TMX-ɣ-CD-MOF-1 and TMX-ɣ-CD-MOF-2 with
particle sizes 606,3±38,40 nm
and 337,8±31,86 nm, respectively.
The solubility of TMX was successfully
increased in pH 1.2, pH 4.5, pH 6.8 and water with ɣ-CD-MOF formulations. TMX-ɣ-CD-MOF-2 found to be more successful in enhancing
solubility of TMX,considered to be a
result of its lower particle size.
Conclusions: ɣ-Cyclodextrin
metal-organic frameworks(ɣ-CD-MOFs)
are promising novel drug delivery systems to enhance solubility hence
dissolution rate of BCS II and IV drugs.
Acknowledgments
This
study was supported by a grant of TÜBİTAK(SBAG-222S923). Şeyma Edisan thanks for
financial support from TÜBITAK(BIDEB/2211-A).
References:
1.Han, Y., Liu, W., Huang,
J., Qiu, S., Zhong, H., Liu, D., & Liu, J. (2018). Cyclodextrin-Based
Metal-Organic Frameworks (CD-MOFs) in Pharmaceutics and Biomedicine.
Pharmaceutics, 10(4), 271.
2. Manna S, Holz MK. Tamoxifen Action in ER-Negative Breast
Cancer. Sign Transduct Insights. 2016 Feb 10;5:1-7.
3.Ravikumara NR,
Bharadwaj M, Madhusudhan B. Tamoxifen citrate-loaded poly(d,l) lactic acid
nanoparticles: Evaluation for their anticancer activity in vitro and in vivo. J
Biomater Appl. 2016 Nov;31(5):755-772.
4. Ağardan,
N. M., Değim, Z., Yılmaz, Ş., Altıntaş, L., & Topal, T. (2020).
Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer.
Journal of Drug Delivery Science and Technology, 57, 101612.